Imunon, Inc. (0HUZ.L)

1,4000 +0,0657 (+4,92%) Alla chiusura: 05:40PM BST

Imunon, Inc.

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100
https://www.imunon.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 33

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael H. Tardugno	Executive Chairman	N/D	N/D	1951
Mr. Jeffrey W. Church CPA	CFO, Executive VP & Corporate Secretary	632,02k	N/D	1957
Dr. Khursheed Anwer M.B.A., Ph.D.	Executive VP & Chief Scientific Officer	632,26k	N/D	1960
Mr. Timothy J. Tumminello CPA	Chief Accounting Officer & Controller	108,31k	N/D	1958
Ms. Marianne M. Lambertson	Vice President of Communications & Investor Relations	N/D	N/D	N/D
Dr. Sebastien Hazard M.D.	Executive VP & Chief Medical Officer	N/D	N/D	1972

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. It also develops ThermoDox, a direct chemotherapy. In addition, the company is developing IMNN-101, a COVID-19 booster vaccine which is in preclinical trials; IMNN-102 for the of the Lassa virus which is in preclinical trials; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. Further, it develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Imunon, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.